Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
Ortholan C, Durivault J, Hannoun-Levi JM, Guyot M, Bourcier C, Ambrosetti D, Safe S, Pagès G.